Backs FY25 adjusted EBITDA view loss of $35M. The company said, ‘The Company expects full year 2025 gross margins in the range of 64.0% to 64.5%. The Company expects a gross margin headwind of approximately $2.0 million in the fourth quarter, attributable to tariff-related costs.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- PRCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Procept Biorobotics’ WATER IV Study: A Game Changer in Prostate Cancer Treatment?
- Procept Biorobotics’ Aquablation Therapy Study: A Potential Game-Changer for Prostate Treatment
- Buy Rating Affirmed Amid Potential Upside and Strategic Leadership Changes
- Procept BioRobotics price target lowered to $50 from $64 at Truist